JAPANESE COHORT STUDY OF FIRST LINE CHEMOTHERAPY (CT) FOR METASTATIC COLORECTAL CANCER (MCRC) CONTAINING FLUOROPYRIMIDINE, OXALIPLATIN AND BEVACIZUMAB: EMERALD STUDY, FIRST REPORT

被引：0
|
作者：
Taku, K. [1 ]
Ohata, K. [1 ]
Yamazaki, K. [2 ]
Nishikawa, G. [1 ]
Watanabe, M. [3 ]
Sato, S. [3 ]
Oshima, T. [3 ]
Hirano, H. [1 ]
Amano, T. [4 ]
Ohashi, Y. [5 ]
机构：
[1] Shizuoka Prefectural Gen Hosp, Div Med Oncol, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
[3] Shizuoka Prefectural Gen Hosp, Div Surg, Shizuoka, Japan
[4] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[5] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [21] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
    Saltz, Leonard B.
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Cassidy, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2013 - 2019
  • [22] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [23] The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer
    Nakamura, Masato
    Yamada, Yasuhide
    Muro, Kei
    Takahashi, Keiichi
    Baba, Hideo
    Sasaki, Yasutsuna
    Komatsu, Yoshito
    Satoh, Taroh
    Mishima, Hideyuki
    Watanabe, Masahiko
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Sugihara, Kenichi
    FUTURE ONCOLOGY, 2015, 11 (10) : 1471 - 1478
  • [24] Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy.: A report of the AIO Colorectal Study Group
    Mueller, C. I.
    Schulmann, K.
    Reinacher-Schick, A.
    Andre, N.
    Arnold, D.
    Tannapfel, A.
    Arkenau, H.
    Hahn, S. A.
    Schmoll, S. H. -J.
    Porschen, R.
    Schmiegel, W.
    Graeven, U.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2008, 23 (11) : 1033 - 1039
  • [25] Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group
    C. I. Müller
    K. Schulmann
    A. Reinacher-Schick
    N. Andre
    D. Arnold
    A. Tannapfel
    H. Arkenau
    S. A. Hahn
    S. H.-J. Schmoll
    R. Porschen
    W. Schmiegel
    U. Graeven
    International Journal of Colorectal Disease, 2008, 23 : 1033 - 1039
  • [26] A first combination phase I study of TAS-102 and irinotecan (hi) in Japanese patients (pts) with metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine (FU) and oxaliplatin (Ox)
    Yamazaki, K.
    Doi, T.
    Yoshino, T.
    Fuse, N.
    Boku, N.
    Koizumi, W.
    Shimada, K.
    Takinishi, Y.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S555 - S555
  • [27] Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer
    Munoz, Alberto
    Pericay, Caries
    Garcia-Giron, Carlos
    Alonso, Vicente
    Duenas, Rosario
    Cirera, Luis
    Rivera, Fernando
    Falco, Esther
    Alvarez Bustos, Inaki
    Salud, Antonieta
    ONCOLOGY RESEARCH, 2013, 21 (04) : 181 - 191
  • [28] First-line bevacizumab and beyond first progression in metastatic Colorectal Carcinoma (mCRC): The KORALLE non-interventional study
    Arnold, D.
    Eggers, E.
    Uhlig, J.
    Reichert, D.
    Becker, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 130 - 130
  • [29] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [30] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
12345